An FDA advisory committee has voted unanimously in favor of approval of the combination type 2 diabetes treatment insulin degludec/liraglutide. The panel also agreed that the combination treatment would at least be appropriate for patients who had previously used an insulin analogue or GLP-1 agonist, but no other consensus was reached regarding which patient types would be suitable candidates. Members of the advisory committee indicated the combination treatment was needed and expressed hope an insulin-containing combination might overcome “insulin inertia” among clinicians.
